Study on Oral Prednisolone and Sucrose for Treating Wheezing Caused by Rhinovirus in Children Under 2 Years Old

3 1 1

What is this study about?

This clinical trial is focused on studying children under 2 years old who experience wheezing caused by a common cold virus known as the rhinovirus. Wheezing is a high-pitched whistling sound made while breathing, often associated with difficulty in breathing. The study aims to determine if a medication called prednisolone sodium phosphate, which is a type of steroid that helps reduce inflammation, can help these children. The treatment involves taking the medication orally, which means it is swallowed in the form of a liquid solution.

During the study, children will receive either the prednisolone sodium phosphate or a placebo, which is a substance with no active medication. The study will last for a short period, and the children will be monitored to see how quickly they recover from wheezing and if they need to stay in the hospital for a shorter time. The goal is to see if the medication helps them get better faster and reduces the need for additional medical care.

Parents and caregivers will be informed about the progress and any changes in the child’s condition throughout the study. The study will also track if the children experience any recurrence of wheezing or other related symptoms over a period of time after the initial treatment. This research is important to find better ways to help young children who suffer from wheezing due to viral infections.

1 study entry

Upon arrival at the hospital, a child aged between 6 months and 2 years is diagnosed with acute wheezing by an emergency department physician.

A nasal swab test confirms the presence of rhinovirus or another picornavirus.

The child must have arrived at the hospital within the past 6 hours and received salbutamol treatment at the emergency department.

2 medication administration

The child receives oral prednisolone sodium phosphate to address the wheezing symptoms.

The dosage and frequency of administration are determined by the medical team based on the child’s specific needs.

3 monitoring and assessment

The primary endpoint is the time difference in minutes between study entry and when the child is deemed fit for discharge.

Secondary endpoints include the total length of hospital stay, any need for intensive care, and the duration of supplemental oxygen use.

The child’s PEWS score is monitored, which assesses various health indicators such as respiratory rate and heart rate.

4 follow-up period

The child is observed for any recurrence of wheezing within 56 days following study enrollment.

Additional follow-ups include monitoring for cough, respiratory distress, and any hospital readmissions or emergency department visits.

Long-term follow-up includes tracking the recurrence of wheezing and any need for asthma medication over a period of up to two years.

Who Can Join the Study?

Children must be between the ages of 6 months and 2 years.
The child must have acute wheezing, which means sudden and severe breathing difficulty, diagnosed by a doctor in the emergency department.
A test must show a positive result for rhinovirus or other picornavirus in a nasal swab. This means the virus causing the wheezing is identified from a sample taken from the nose.
The child must have arrived at the hospital within the past 6 hours.
The child must have received salbutamol treatment at the emergency department. Salbutamol is a medication used to help open the airways and make breathing easier.

Who Cannot Join the Study?

Children who are not between 6 months and 2 years old.
Children who do not have wheezing caused by a virus called rhinovirus or other similar viruses.
Children who have not been tested for these viruses at the emergency department.
Children who have other medical conditions that might interfere with the study.
Children who are taking medications that could affect the study results.
Children who have allergies to the study medication, which is called oral prednisolone. This is a type of medicine that helps reduce inflammation and swelling.
Children whose parents or guardians do not agree to participate in the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Oulu University Hospital	Oulu	Finland
Kytgwccmpfgctrrx hiezbynmebvghad	Kokkola	Finland

Trial status

Country	Status	Recruitment Start
Finland	Recruiting	01.10.2022

Trial locations

Investigated drugs:

Prednisolone is a medication used in this trial to help children who are experiencing acute wheezing due to a rhinovirus or other picornavirus infection. The study aims to see if giving oral prednisolone to children aged 6 months to 2 years can improve their symptoms. Prednisolone is a type of steroid that can reduce inflammation and help with breathing difficulties.

Investigated diseases:

Wheezing

Rhinovirus-induced Wheezing – This condition occurs when the rhinovirus, a common cause of the cold, triggers wheezing in the respiratory system. It is particularly prevalent in young children and can lead to episodes of difficulty breathing. The wheezing is caused by the narrowing of airways due to inflammation and increased mucus production. Symptoms may include a whistling sound when breathing, shortness of breath, and coughing. The condition can vary in severity, with some children experiencing mild symptoms and others having more significant respiratory distress. It often requires monitoring to manage symptoms and prevent complications.

Trial ID:

2024-512561-13-00

NCT ID:

NCT05444699

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Oral Prednisolone and Sucrose for Treating Wheezing Caused by Rhinovirus in Children Under 2 Years Old

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?